Literature DB >> 22159222

MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma.

Soichiro Yamamura1, Sharanjot Saini, Shahana Majid, Hiroshi Hirata, Koji Ueno, Inik Chang, Yuichiro Tanaka, Ashish Gupta, Rajvir Dahiya.   

Abstract

We investigated the functional effects of microRNA-34a (miR-34a) on c-Myc transcriptional complexes in renal cell carcinoma. miR-34a down-regulated expression of multiple oncogenes including c-Myc by targeting its 3' untranslated region, which was revealed by luciferase reporter assays. miR-34a was also found to repress RhoA expression by suppressing the c-Myc-Skp2-Miz1 transcriptional complex that activates RhoA. Overexpression of c-Myc reversed miR-34a suppression of RhoA expression and inhibition of cell invasion, suggesting that miR-34a inhibits invasion by suppressing RhoA through c-Myc. miR-34a was also found to repress the c-Myc-P-TEFb transcription elongation complex, indicating one of the mechanisms by which miR-34a has profound effects on cellular functions. Our results demonstrate that miR-34a suppresses assembly and function of the c-Myc complex that activates or elongates transcription, indicating a novel role of miR-34a in the regulation of transcription by c-Myc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22159222      PMCID: PMC3271269          DOI: 10.1093/carcin/bgr286

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  45 in total

Review 1.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

Review 2.  RHO-GTPases and cancer.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

3.  Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.

Authors:  S H Chao; D H Price
Journal:  J Biol Chem       Date:  2001-06-28       Impact factor: 5.157

4.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.

Authors:  Randolph S Watnick; Yi-Ning Cheng; Annapoorni Rangarajan; Tan A Ince; Robert A Weinberg
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

5.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

6.  Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.

Authors:  Markus Vogt; Johanna Munding; Martha Grüner; Sven-Thorsten Liffers; Berlinda Verdoodt; Jennifer Hauk; Lars Steinstraesser; Andrea Tannapfel; Heiko Hermeking
Journal:  Virchows Arch       Date:  2011-01-12       Impact factor: 4.064

7.  Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion.

Authors:  Jennelle C Hodge; Jeffrey Bub; Sushma Kaul; André Kajdacsy-Balla; Paul F Lindholm
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

8.  Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter.

Authors:  Scott R Eberhardy; Peggy J Farnham
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

9.  c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis.

Authors:  Satoshi Kanazawa; Laura Soucek; Gerard Evan; Takashi Okamoto; B Matija Peterlin
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

10.  Quantitative proteomic analysis of Myc oncoprotein function.

Authors:  Yuzuru Shiio; Sam Donohoe; Eugene C Yi; David R Goodlett; Ruedi Aebersold; Robert N Eisenman
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

View more
  35 in total

Review 1.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

2.  Unveiling the principle of microRNA-mediated redundancy in cellular pathway regulation.

Authors:  Simon Fischer; René Handrick; Armaz Aschrafi; Kerstin Otte
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  MicroRNA-based screens for synthetic lethal interactions with c-Myc.

Authors:  Youjun Li; Yahui Zhu; Edward V Prochownik
Journal:  RNA Dis       Date:  2016-05-30

4.  MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.

Authors:  Emelyn H Shroff; Livia S Eberlin; Vanessa M Dang; Arvin M Gouw; Meital Gabay; Stacey J Adam; David I Bellovin; Phuoc T Tran; William M Philbrick; Adolfo Garcia-Ocana; Stephanie C Casey; Yulin Li; Chi V Dang; Richard N Zare; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

Review 5.  The regulation and function of microRNAs in kidney diseases.

Authors:  Qingqing Wei; Qing-Sheng Mi; Zheng Dong
Journal:  IUBMB Life       Date:  2013-07       Impact factor: 3.885

6.  Elevated miR-182-5p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT-1 Expression.

Authors:  Priyanka Kulkarni; Pritha Dasgupta; Nadeem S Bhat; Varahram Shahryari; Marisa Shiina; Yutaka Hashimoto; Shahana Majid; Guoren Deng; Sharanjot Saini; Z Laura Tabatabai; Soichiro Yamamura; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Mol Cancer Res       Date:  2018-07-23       Impact factor: 5.852

7.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

8.  MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).

Authors:  Jiali Zhang; Yu Wang; Xinming Chen; Yi Zhou; Fangyan Jiang; Jirong Chen; Li Wang; Wen-Feng Zhang
Journal:  Oncotarget       Date:  2015-04-10

9.  miR-15b/16-2 regulates factors that promote p53 phosphorylation and augments the DNA damage response following radiation in the lung.

Authors:  Mohammad Rahman; Francesca Lovat; Giulia Romano; Federica Calore; Mario Acunzo; Erica Hlavin Bell; Patrick Nana-Sinkam
Journal:  J Biol Chem       Date:  2014-08-04       Impact factor: 5.157

10.  Downregulation of HMGB1 by miR-34a is sufficient to suppress proliferation, migration and invasion of human cervical and colorectal cancer cells.

Authors:  Karthik Subramanian Chandrasekaran; Anusha Sathyanarayanan; Devarajan Karunagaran
Journal:  Tumour Biol       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.